According to the research report titled ‘Hemophilia Treatment Market Size By Disease (Hemophilia A {Severe, Moderate, Mild}, Hemophilia B {Severe, Moderate, Mild}), By Product (Recombinant Factor Concentrates {Factor VIII, Factor IX}, Plasma-derived Factor Concentrates {Factor VIII, Factor IX}, Extended Half-life Products {Factor VIII, Factor IX}), By Patient (Pediatric {0 to 4, 5 to 13, 14 to18}, Adult {19 to 44, 45+}), By Treatment (Prophylaxis, On Demand), By Therapy (Factor Replacement Therapy, Non-factor Replacement Therapy), By Drug Class (Vasopressin, Coagulation Factors), By Route of Administration (Injectable, Nasal Spray), By End-use (Hospitals, Clinics, Hemophilia Treatment Centers), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Italy, Russia, Poland, Hungary, Czech Republic, Finland, Greece, Ireland, Portugal, Sweden, Switzerland, Ukraine, Norway, Slovakia, China, Japan, India, Australia, South Korea, Malaysia, Philippines, Thailand, Vietnam, Singapore, Brazil, Mexico, Argentina, Columbia, Chile, Venezuela, South Africa, Saudi Arabia, Egypt, Iran, Iraq, UAE), Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 – 2025’, available at MarketStudyReport.com, the global hemophilia treatment market is expected to surpass USD 14.8 billion by the year 2025.
 

According to the report, rising prevalence of bleeding disorders such as hemophilia is a major factor driving the growth of hemophilia treatment market. Various governments across the globe are encouraging diagnosis programs for hemophilia disorders. This factor coupled with rising R&D activities in order to develop innovative drugs are aiding the expansion of the market.
 

Increasing utilization of prophylaxis treatment methods by patients suffering from hemophilia is also stimulating the industry outlook. However, high costs of hemophilia drugs may hinder the market growth. Moreover, dearth of appropriate hemophilia treatment and lack of awareness in developing countries may impede the growth of the market.
 

By product type, recombinant factor concentrates segment is presumed to grow with a CAGR of 5% during the period of 2019-2025. This type of product enhances the safety of replacement therapy and helps in preventing viral infections, thereby fueling the segmental growth.
 

In terms of treatment type, the report states that prophylaxis treatment segment accounted for USD 7,219.9 million in the year 2018 and is expected to register continuous growth in the forthcoming years. Prophylaxis treatment methods give better results when compared to their counterparts, which in turn is contributing towards the popularity of the treatment method across the globe.
 

Request sample copy of this Report@ https://www.marketstudyreport.com/request-a-sample/2100697/
 

As per regional analysis, U.S. hemophilia treatment market was worth USD 3,539.3 million in the year 2018. Favorable reimbursement policies for hemophilia treatment have led to rising adoption of such treatment methods across the country. Meanwhile, India hemophilia treatment market is estimated to expand with a CAGR of 9.2% between 2019 and 2025. Favorable government measures, escalating healthcare expenditure, and increasing awareness are leading to the growth of the market in India.
 

Swedish Orphan Biovitrum AB, Sanofi SA, Pfizer, Octapharma, Novo Nordisk, Kedrion, Genentech, Ferring B. V., CSL Behring, Biotest AG, Biogen and Bayer Healthcare are the prominent companies operating in the hemophilia treatment market.